FSD Pharma has filed an application with the US Food and Drug Administration (FDA) seeking its approval to launch a phase 2 trial for FSD201 (ultramicronised palmitoylethanolamide, or ultramicronised PEA) in Covid-19 patients.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,